88.5 WFDD Web Archives
WFDD Archive
Main WFDD Website News Archives Triad Arts Archives Real People Archives Sports Commentary Archives Business Report Archives  

You are visiting the WFDD web archives.

Click here to return to our main website with the latest news from WFDD and NPR.

Search the WFDD archives
 

The Business Report
Targacept's Lead Compound Ties Placebo

November 11, 2011 | David Ford

Targacept, with over 140 employees is the Piedmont Triad Research Park’s flagship biotech company. CEO, Don deBethizy spun the drug-discovery company out of R.J. Reynolds Tobacco Co. 11 years ago, and it’s been growing steadily ever since.

Targacept has an enormous pipeline of new drugs at various stages of completion that deal with brain disorders from Alzheimer’s to Parkinson’s. One of them is the company's lead compound, an antidepressant named TC-5214—its first to reach the final stage of clinical trials. On Tuesday, while still in that stage, 5214 met with a major set back.

Last week Business Journal Contributing Writer and Director of the Journalism Program at Wake Forest University Justin Catanoso spoke with deBethizy about the challenges and promise of bringing a new drug to market. Justin shared that conversation with WFDD’s David Ford.

Full archive of The Business Report >>


<< earlier stories  
<< February 2011 >>
Su M T W Th F Sa
  12345
6789101112
13141516171819
20212223242526
27282930   

Show month: